Scarica l'app Stockscreener
3.64
7.37%
0.25
Precedente Chiudi:
$3.39
Aprire:
$3.4
Volume 24 ore:
793.29K
Relative Volume:
1.17
Capitalizzazione di mercato:
$251.03M
Reddito:
$8.38M
Utile/perdita netta:
$-27.19M
Rapporto P/E:
-3.3394
EPS:
-1.09
Flusso di cassa netto:
$-13.59M
1 W Prestazione:
+20.93%
1M Prestazione:
+70.09%
6M Prestazione:
+230.91%
1 anno Prestazione:
+216.52%
Intervallo 1D:
$3.37
$3.70
Intervallo di 1 settimana:
$3.01
$3.70
Portata 52W:
$0.65
$3.70
Opus Genetics Inc Stock (IRD) Company Profile
Nome
Opus Genetics Inc
Settore
Industria
Telefono
248-681-9815
Indirizzo
8 DAVIS DRIVE, DURHAM
Compare IRD vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
3.64 | 233.79M | 8.38M | -27.19M | -13.59M | -1.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-20 | Iniziato | BTIG Research | Buy |
| 2025-12-10 | Iniziato | B. Riley Securities | Buy |
| 2025-11-25 | Iniziato | Piper Sandler | Overweight |
| 2025-10-29 | Iniziato | Wedbush | Outperform |
| 2025-10-16 | Iniziato | Chardan Capital Markets | Buy |
| 2025-04-11 | Iniziato | Craig Hallum | Buy |
| 2024-11-13 | Ripresa | H.C. Wainwright | Buy |
Mostra tutto
Opus Genetics Inc Borsa (IRD) Ultime notizie
Aug Macro: Why Opus Genetics Inc. (R3X1) stock could rally stronglyJuly 2025 Weekly Recap & Long-Term Safe Investment Ideas - mfd.ru
Opus Genetics (NASDAQ:IRD) Raised to Strong-Buy at Lifesci Capital - Defense World
Opus Genetics raises $25 million in private placement financing By Investing.com - Investing.com Nigeria
Opus Genetics, Inc. announced that it expects to receive $25.000002 million in funding - marketscreener.com
Opus Genetics higher after $25M private placement - MSN
Opus Genetics announces $25 million private placement - marketscreener.com
Opus Genetics Announces $25 Million Private Placement - TradingView
Opus Genetics raises $25 million in private placement financing - Investing.com
Opus Genetics lands $25M to advance gene therapies to prevent blindness - Stock Titan
Will Opus Genetics Inc. (R3X1) stock benefit from commodity supercycleQuarterly Trade Summary & Free Reliable Trade Execution Plans - mfd.ru
Aug Big Picture: Is Opus Genetics Inc a strong growth stock2025 Key Highlights & AI Powered Market Entry Ideas - baoquankhu1.vn
Revenues Not Telling The Story For Opus Genetics, Inc. (NASDAQ:IRD) After Shares Rise 43% - simplywall.st
Aug Opening: Is Opus Genetics Inc a strong growth stock2025 Price Targets & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Opus Genetics, Inc. (NASDAQ:IRD) Short Interest Update - MarketBeat
Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026 - The Manila Times
Why Opus Genetics Inc. (R3X1) stock could rally stronglyJuly 2025 Rallies & Weekly High Momentum Picks - mfd.ru
Opus Genetics' (IRD) "Buy" Rating Reiterated at BTIG Research - MarketBeat
Where Opus Genetics Stands With Analysts - Benzinga
Opus Genetics to begin MERTK gene therapy trial in Abu Dhabi - Investing.com India
Opus Genetics (IRD) Initiates Gene Therapy Trial for Eye Disorder - GuruFocus
Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa - The Manila Times
Fundamentals Check: Is TrueCar Inc. a stock for growth or value investorsExit Point & Low Volatility Stock Recommendations - baoquankhu1.vn
Opus Genetics, Inc. (NASDAQ:IRD) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Opus Genetics, Inc. (NASDAQ:IRD) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Take Profit: Is Opus Genetics Inc benefiting from innovation trendsJuly 2025 Outlook & AI Powered Market Trend Analysis - baoquankhu1.vn
BTIG Research Begins Coverage on Opus Genetics (NASDAQ:IRD) - Defense World
Opus Genetics (NASDAQ:IRD) Stock Rating Upgraded by BTIG Research - MarketBeat
BTIG Initiates Coverage of Opus Genetics (IRD) with Buy Recommendation - Nasdaq
Opus Genetics stock initiated with Buy rating at BTIG on retinal disease focus - Investing.com Canada
BTIG Initiates Coverage on Opus Genetics (IRD) with a Buy Rating - GuruFocus
Wall Street Zen Upgrades Opus Genetics (NASDAQ:IRD) to Hold - MarketBeat
JPM26: Opus Genetics builds momentum in rare retinal gene therapy - Yahoo Finance
Opus Genetics, Inc. Announces Presentation at J.P. Morgan Healthcare Conference - TradingView
Virtual Reality Endpoints Improve Measurement Of Patients' Real-World Benefit - Clinical Leader
Opus Genetics highlights 2025 progress, upcoming 2026 catalysts - Yahoo Finance
How Opus Genetics Inc. stock reacts to oil pricesWeekly Profit Report & Risk Controlled Daily Trade Plans - Улправда
Merger Talk: How cyclical is Opus Genetics Inc. (R3X1) stock compared to rivalsTrade Risk Summary & Free Accurate Trade Setup Notifications - Улправда
How cyclical is Opus Genetics Inc. (R3X1) stock compared to rivals2025 Momentum Check & Community Verified Watchlist Alerts - Улправда
Earnings Risk: Is Opus Genetics Inc. stock attractive for growth ETFsPortfolio Performance Summary & Free Community Supported Trade Ideas - Улправда
How interest rate cuts could boost Opus Genetics Inc. stock2025 Major Catalysts & Weekly Stock Performance Updates - Улправда
Opus Genetics (IRD) Advances Clinical Trials and Regulatory Fili - GuruFocus
Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts - The Manila Times
Opus Genetics Details 2025 Progress and 2026 Milestones - TipRanks
Opus Genetics Highlights 2025 Progress and 2026 Catalysts - TradingView — Track All Markets
Opus Genetics (NASDAQ:IRD) Cut to Sell at Wall Street Zen - Defense World
Independent Chairman of Opus Genetics Picks Up 9.5% More Stock - simplywall.st
Caprolactam Chemicals Limited Stock Analysis Technical Signals for YEAR - earlytimes.in
What drives Opus Genetics Inc stock priceEx-Dividend Date Alerts & Small Investment Portfolio - earlytimes.in
Hedge Fund and Insider Trading News: Ken Griffin, Warren Buffett, Bridgewater Associates, AQR Capital Management, Schonfeld Strategic Advisors, D.E. Shaw, Millennium Management, Elliott Management, Discovery Capital Management, Opus Genetics Inc - Insider Monkey
Opus Genetics Advances Gene Therapy for Retinal Degeneration: A Study Update - MSN
Opus Genetics Inc Azioni (IRD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Opus Genetics Inc Azioni (IRD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Gallagher Cam | Director |
Dec 29 '25 |
Buy |
1.98 |
81,000 |
160,275 |
1,891,430 |
| Foundation Fighting Blindness | Director |
Dec 09 '25 |
Sale |
2.15 |
4,000,000 |
8,600,000 |
5,492,171 |
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):